Diagnosis of autoimmune liver disease can be challenging. In this test-specific episode of the "Answers From the Lab" podcast, Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune hepatitis, primary biliary cholangitis (PBC), and liver disease of unknown etiology.

"The disease spectrum is broad, and disease boundaries may be blurred by overlapping features," Dr. Tebo says. "The panel should ideally be requested following observation of abnormal liver enzymes, as well as for the elimination of common causes of liver disease such as metabolic, genetic, viral, drug, or alcohol-induced hepatitis."

The assay includes tests for two types of antibodies associated with autoimmune hepatitis and one type that is highly suggestive of PBC. Test results should be interpreted in the context of clinical assessment.

"Detection of these antibodies in asymptomatic patients may suggest risk for future disease development, which would require close monitoring for disease onset," Dr. Tebo says.

Listen to learn more about Mayo Clinic Laboratories' ALDG2 assay.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

ALDG2   | Autoimmune Liver Disease Panel, Serum

Useful information

Evaluating patients with suspected autoimmune liver disease, specifically autoimmune hepatitis or primary biliary cholangitis.

Evaluating patients with liver disease of unknown etiology.

Specimen requirements

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.

Performance information

• Analytic time: 3 - 4 days
• Day(s) and time(s) performed: Monday through Saturday

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less